SIGA Technologies Inc. reports developments as a commercial-stage pharmaceutical company focused on infectious-disease countermeasures, with a primary focus on orthopoxviruses. Its recurring updates center on TPOXX (tecovirimat), including oral and IV product sales, deliveries to large institutional customers and international governments, Strategic National Stockpile activity, and procurement contracts.
Company news also covers quarterly and annual results, research and development revenue, BARDA 19C development funding for pediatric and manufacturing activities, regulatory developments for tecovirimat indications, business update calls, and capital actions such as special cash dividends on common stock.
SIGA Technologies has announced an agreement to sell its antiviral drug TPOXX (tecovirimat) to ASEAN member states. The agreement was signed by the Ministry of Health of Brunei Darussalam on behalf of ASEAN, reflecting a collective effort to prepare for public health events such as Mpox and smallpox. This collaboration with Meridian Medical Technologies aims to ensure an adequate supply of TPOXX in the region, which comprises over 600 million people with a GDP of $3.6 trillion. Financial details of the agreement were not disclosed.
Calidi Biotherapeutics has partnered with SIGA Technologies to advance its RTNova virotherapy for lung cancer and metastatic solid tumors. RTNova leverages a vaccinia virus enveloped by a human cell membrane to evade immunity and enhance therapeutic functions. SIGA will supply TPOXX, an antiviral agent against vaccinia virus, to support RTNova's development. This collaboration aims to create a universal treatment for all tumor types and will initially focus on lung cancer and metastatic solid tumors. RTNova's novel approach allows for easy administration and a broader patient reach. The partnership offers a safety mechanism for clinical trials, ensuring better regulatory compliance and patient safety.
SIGA Technologies, Inc. reported strong financial results for Q1 2024, with $24 million in product sales and $11 million in pre-tax operating income, showcasing growth over the previous year. The company highlighted focus on financial and operational excellence, TPOXX® franchise value, and team resilience. Recent developments include a new drug application in Japan and an amendment with Meridian Medical Technologies. SIGA also delivered $24 million of oral TPOXX in Q1, with a special cash dividend of $0.60 per share declared. The conference call and webcast to provide a business update are scheduled for May 7, 2024.
SIGA Technologies, a pharmaceutical company, will host a business update call on May 7, 2024, following the release of their first-quarter financial results. The call will feature the CEO and CFO and will be available via webcast and conference call. Participants can access the call through the company's website or by dialing in. A replay will be available for two weeks.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.